Stock ARMP ARMATA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Armata Pharmaceuticals, Inc.

Equities

ARMP

US04216R1023

Market Closed - Nyse
Other stock markets
 04:00:00 2024-06-10 pm EDT 		5-day change 1st Jan Change
2.65 USD -2.57% Intraday chart for Armata Pharmaceuticals, Inc. -3.64% -18.21%
May. 07 Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 07 Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000 MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
ARMATA PHARMACEUTICALS, INC. Stock Armata Pharmaceuticals, Inc.
-18.21% 95.81M -
MODERNA, INC. Stock Moderna, Inc.
+49.41% 56.95B
B-
LONZA GROUP AG Stock Lonza Group AG
+40.06% 40.26B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-6.72% 39.32B
B
CELLTRION, INC. Stock Celltrion, Inc.
-5.96% 28.37B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.99% 26.45B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-19.82% 19.41B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.35% 12.54B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.18% 12.21B
B+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-0.08% 12.15B
B+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. ARMP Stock
  4. Ratings Armata Pharmaceuticals, Inc.